Infliximab does not interfere with insulin secretion, insulin resistance and production of GAD and islet cell antibodies in patients with Crohn's disease.
Gentile
S
S
Department of Geriatrics and Metabolic Disease, Second University of Naples, Italy. sandro.gentile@unima2.it
Guarino
G
G
Bizzarro
A
A
De Bellis
A
A
Torella
R
R
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood*; D003424:Crohn Disease / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005968:Glutamate Decarboxylase / Q000097:blood; D006801:Humans; D000069285:Infliximab; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D007333:Insulin Resistance / Q000502:physiology*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000276:immunology; D008297:Male; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D005765:Gastrointestinal Agents; D007328:Insulin; C024211:islet cell antibody; D000069285:Infliximab; D005968:Glutamate Decarboxylase